Can Merck’s IDVYNSO agreement widen HIV treatment access across state programmes?
See how Merck’s IDVYNSO ADAP agreement could widen HIV treatment access while pricing, formularies and clinical limits shape uptake.
Pharma & Biotech
Pharma & Biotech
FDA approval of IDVYNSO gives Merck a fresh HIV story, but will clinicians switch stable patients?
Merck’s IDVYNSO has won FDA approval in HIV. Read what the new two-drug regimen changes, where it fits, and what risks still matter.